An immunoprophylactic evaluation of<i>Ld</i>-ODC derived HLA-A0201 restricted peptides against visceral leishmaniasis

Pandey, R. K.; Dikhit, Manas Ranjan; Lokhande, Kiran Bharat; Pandey, Krishna; Das, Pradeep; Bimal, Sanjiva

doi:10.1080/07391102.2021.1876773

Cited by 2 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, none of them retain their protective efficiency in human clinical trials [ 9 , 10 , 31 ]. In our previous study, the vaccine potential of the r- Ld ODC protein and its derived synthetic peptides has been validated in vitro against VL [ 16 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

“…As mentioned in the literature, the polyamine biosynthesis pathway and its derived byproducts played a crucial role in the survival and proliferation of the Leishmania parasite [ 23 , 24 , 25 ]. An in vitro and in vivo experiment study reported that ODC protein, a rate-limiting enzyme of polyamine biosynthesis pathway [ 26 ], ODC DNA construct [ 27 ], as well as its derived synthetic peptides [ 16 , 28 ] have the potential to generate a significant amount of pro-inflammatory cytokines and promote protection against Leishmania infection. Another study reported HIV-1 reverse transcriptase (RT) with fused ornithine decarboxylase (ODC) as a potential vaccine candidate as it strengthened a strong Th1 immune response against HIV in mice models [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validating Immunomodulatory Responses of r-LdODC Protein and Its Derived HLA-DRB1 Restricted Epitopes against Visceral Leishmaniasis in BALB/c Mice

et al. 2022

View full text Add to dashboard Cite

Vaccination is considered the most appropriate way to control visceral leishmaniasis (VL). With this background, the r-LdODC protein as well as its derived HLA-DRB1-restricted synthetic peptides (P1: RLMPSAHAI, P2: LLDQYQIHL, P3: GLYHSFNCI, P4: AVLEVLSAL, and P5: RLPASPAAL) were validated in BALB/c mice against visceral leishmaniasis. The study was initiated by immunization of the r-LdODC protein as well as its derived peptides cocktail with adjuvants (r-CD2 and MPL-A) in different mice groups, separately. Splenocytes isolated from the challenged and differentially immunized mice group exhibited significantly higher IFN-γ secretion, which was evidenced by the increase in the expression profile of intracellular CD4+IFN-γ T cells. However, the IL-10 secretion did not show a significant increase against the protein and peptide cocktail. Subsequently, the study confirmed the ability of peptides as immunoprophylactic agents, as the IE-I/AD-I molecule overexpressed on monocytes and macrophages of the challenged mice group. The parasitic load in macrophages of the protein and peptides cocktail immunized mice groups, and T cell proliferation rate, further established immunoprophylactic efficacy of the r-LdODC protein and peptide cocktail. This study suggests that the r-LdODC protein, as well as its derived HLA-DRB1-restricted synthetic peptides, have immunoprophylactic potential and can activate other immune cells’ functions towards protection against visceral leishmaniasis. However, a detailed study in a humanized mice model can explore its potential as a vaccine candidate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Validating Immunomodulatory Responses of r-LdODC Protein and Its Derived HLA-DRB1 Restricted Epitopes against Visceral Leishmaniasis in BALB/c Mice

et al. 2022

View full text Add to dashboard Cite

show abstract

Potential Molecular Targets of Leishmania Pathways in Developing Novel Antileishmanials

Ramu

Singh

2021

Future Microbiol.

View full text Add to dashboard Cite

The illness known as leishmaniasis has not become a household name like malaria, although it stands as the second-largest parasitic disease, surpassed only by malaria. As no licensed vaccine is available, treatment for leishmaniasis mostly relies on chemotherapy. Inefficiency and drug resistance are the major impediments in current therapeutics. In this scenario, identification of novel molecular drug candidates is indispensable to develop robust antileishmanials. The exploration of structure-based drugs to target enzymes/molecules of Leishmania which differ structurally/functionally from their equivalents in mammalian hosts not only helps in developing a new class of antileishmanials, but also paves the way to understand Leishmania biology. This review provides a comprehensive overview on possible drug candidates relating to various Leishmania molecular pathways.

show abstract

An immunoprophylactic evaluation ofLd-ODC derived HLA-A0201 restricted peptides against visceral leishmaniasis

Cited by 2 publications

References 54 publications

Validating Immunomodulatory Responses of r-LdODC Protein and Its Derived HLA-DRB1 Restricted Epitopes against Visceral Leishmaniasis in BALB/c Mice

Validating Immunomodulatory Responses of r-LdODC Protein and Its Derived HLA-DRB1 Restricted Epitopes against Visceral Leishmaniasis in BALB/c Mice

Potential Molecular Targets of Leishmania Pathways in Developing Novel Antileishmanials

Contact Info

Product

Resources

About